ClinicalTrials.gg
CompletedNCT00661167Updated Jan 18, 2012

Phase II Study of ABI-007 for Gastric Cancer

A Phase 2 interventional study of ABI-007 in Gastric Cancer, sponsored by Taiho Pharmaceutical Co., Ltd.. Completed at 10 sites in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2012-01-18.

Sponsored by Taiho Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
20 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing Albumin-Bound Paclitaxel in Stomach Neoplasms — 3 open to participants now, 3 under way, none of them phase 3. Albumin-Bound Paclitaxel · Stomach Neoplasms.

Enrollment
6th of 17
56 · median 39
Started
2008
the only one that year
Phase 2
10 of 17
2 open now
Registered
2nd of 17
by date

Among the 17 studies testing Albumin-Bound Paclitaxel in Stomach Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2008, is one of 10 in phase 2, and was the 2nd registered.

Stomach Neoplasms

3,401 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

3 of the 17 studies testing Albumin-Bound Paclitaxel in Stomach Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 20 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing Albumin-Bound Paclitaxel in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of tri-weekly ABI-007 for recurrence or unresectable gastric cancer patients who have received one prior regimen containing fluoropyrimidine and developed disease progression or recurrence.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed gastric adenocarcinoma
  • Received one prior regimen containing fluoropyrimidine analogs and developed disease progression or recurrence
  • Age: 20 - 74
  • At least one by criteria

Exclusion criteria

Exclusion Criteria:

  • History of Taxans use
  • Patients with another active
  • Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per )
  • Chronic treatment with
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    1

    ABI-007

    Drug: ABI-007

Interventions

  • ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.

06

What researchers measure

Primary outcomes

  1. Overall response rate

    Time frame: During chemotherapy

Secondary outcomes

  1. Safety

    Time frame: During chemotherapy

  2. Progression-free survival

    Time frame: Until progression

  3. Overall survival

    Time frame: Over a year form randomaization

  4. Disease control rate

    Time frame: Duration chemoterapy

07

Study locations

10 sites
  • Aichi Cancer Center
    Nagoya, Aichi 464-8681, Japan
  • Shikoku Cancer Center
    Matsuyama, Ehime 791- 0280, Japan
  • Kitasato University East Hospital
    Sagamihara, Kanagawa 228-8520, Japan
  • Saku Central Hospital Nagano Prefectural Federation of Agricultural Cooperatives for Health and Welfare
    Saku, Nagano 384-0301, Japan
  • Osaka Medical College Hospital
    Takatsuki, Osaka 569- 8686, Japan
  • Saitama International medical center-comprehensive cancer center, Saitama Medical University
    Hidaka, Saitama 350-1298, Japan
  • Shizuoka Cancer Center
    Sunto, Shizuoka 411- 8777, Japan
  • Kouseiren Takaoka Hospital
    Takaoka, Toyama 933- 8555, Japan
  • National Kyusyu Cancer Center
    Fukuoka, 811- 1395, Japan
  • Kochi Health Sciences Center
    Kochi, 781- 855, Japan
08

References and documents

Publications

  • Sasaki Y, Nishina T, Yasui H, Goto M, Muro K, Tsuji A, Koizumi W, Toh Y, Hara T, Miyata Y. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci. 2014 Jul;105(7):812-7. doi: 10.1111/cas.12419. Epub 2014 Jul 7. PubMed 24716542 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of May 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2008
First posted
Apr 18, 2008
Start
Apr 2008
Primary completionActual
May 2011
CompletionActual
Dec 2011
Last update
Jan 18, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00661167
Responsible party
Sponsor
First posted
Apr 18, 2008
Start date
Apr 2008
Primary completion
May 2011
Completion
Dec 2011
Last update
Jan 18, 2012

Study contacts

Nagahiro Saijo, MD
study chair · Kinki University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion